Welcome to our dedicated page for Syros Pharmaceuticals news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals stock.
Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.
At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.
While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.
Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.
Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.
Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Pivotal Complete Response (CR) data from SELECT-MDS-1 Phase 3 trial expected by mid-Q4 2024.
2. Additional data from SELECT-AML-1 Phase 2 trial expected in September 2024.
3. Q2 2024 net loss of $23.3 million, or $0.59 per share, compared to $36.3 million, or $1.30 per share, in Q2 2023.
4. Cash, cash equivalents, and marketable securities of $79.0 million as of June 30, 2024.
5. Current funds expected to support operations into Q3 2025, beyond pivotal Phase 3 data readouts.
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company focusing on hematologic malignancies, has announced its upcoming second quarter 2024 financial results report. The company will host a live conference call and webcast on Wednesday, July 31, 2024, at 8:30 a.m. ET to present the results and provide a business update. Interested parties can access the call via phone or webcast, with details available on the company's website. An archived replay of the webcast will be accessible for approximately 30 days after the call.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a webcast on June 25, 2024, from 11:00 a.m. to 12:30 p.m. ET to discuss higher-risk myelodysplastic syndrome (HR-MDS) and the potential of tamibarotene as a new frontline treatment for patients with RARA gene overexpression. Three medical experts will join Syros’ leadership to provide an overview of patient management, current and future treatment landscapes, and tamibarotene's opportunity. Syros is evaluating tamibarotene in pivotal Phase 3 SELECT-MDS-1 and Phase 2 SELECT-AML-1 trials, with pivotal data expected by mid-Q4 2024 and clinical activity and tolerability data by Q3 2024. The event will include presentations on HR-MDS disease overview, current therapies, trial outcomes, and tamibarotene’s mechanism of action.
Syros Pharmaceuticals (SYRS) reported its first-quarter 2024 financial results and provided a corporate update. The company highlighted passing an interim futility analysis in the Phase 3 SELECT-MDS-1 trial, with pivotal CR data expected by mid-Q4 2024. Additionally, the FDA granted Fast Track designation for Tamibarotene in unfit AML. Financially, Syros recorded no revenue compared to $3 million in Q1 2023, and a net loss of $3.7 million, significantly reduced from $23.8 million the previous year. R&D expenses were $24.7 million, down from $28.8 million, while G&A expenses also decreased from $7.4 million to $6.3 million. The company’s cash position was $108.3 million as of March 31, 2024, sufficient to fund operations into Q3 2025.
Syros Pharmaceuticals (SYRS) will participate in two upcoming investor conferences to discuss advancements in the treatment of hematologic malignancies. The company's management will engage in a fireside chat at the JMP Securities 2024 Life Sciences Conference on May 14 and the TD Cowen’s 5th Annual Oncology Innovation Summit on May 29. Interested parties can access webcasts and archived recordings of the events on the Syros website.
Syros Pharmaceuticals (NASDAQ:SYRS) will report its first quarter 2024 financial results on Tuesday, May 14, 2024, with a live conference call and webcast scheduled. The company aims to advance new standards of care for hematologic malignancies.
FAQ
What is the current stock price of Syros Pharmaceuticals (SYRS)?
What is the market cap of Syros Pharmaceuticals (SYRS)?
What does Syros Pharmaceuticals specialize in?
What is unique about Syros Pharmaceuticals' approach?
In which therapeutic areas has Syros Pharmaceuticals shown success?
What recent achievements has Syros Pharmaceuticals made?
What is the financial condition of Syros Pharmaceuticals?
What is the proprietary platform of Syros Pharmaceuticals?
How does Syros Pharmaceuticals impact patient treatment?
Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?
Who are the key contributors to Syros Pharmaceuticals' proprietary platform?
What is the mission of Syros Pharmaceuticals?
